severely ill people compassionate use basis united states special program funded biomedical advanced research development authority barda provided convalescent plasma basis 66,000 people running control groups program investigators including joyner gathering data published results 5,000 people severe covid-19 suggesting therapy broadly safe not know happening use compassionate basis says chowdhury use convalescent plasma clinical trial researchers complained barda funded project siphoned away potential participants plasma donors randomized clinical trials produce rigorous data absence control group joyner colleagues taken advantage fact concentration sars cov-2 antibodies not standardized team looked 35,000 plasma recipients compared results received plasma relatively low levels antibodies findings